Pressure BioSciences (OTCQB: PBIO) (“PBI”), a global leader in the development and sale of broadly enabling, high-pressure-based equipment, consumable products and specialty services to the life sciences, nutraceuticals, cosmeceuticals, and other industries, today provided a progress update on its April 21, 2023, announcement. On that day, the company announced its strategic decision to offer up to five exclusive statewide THC-processing licenses to its revolutionary, patented UltraShear Technology(TM) (UltraShear(TM) or UST(TM)) platform for the preparation of oil-soluble THC concentrates into long-term stable, effectively water-soluble, and highly bioavailable nanoemulsions of THC oil in water. “Completing the sale of these five licenses is expected to generate $5,000,000 or more of topline, non-dilutive revenue for PBIO,” said Richard T. Schumacher, CEO and president of PBI. “These funds will facilitate our rapid production of UltraShear equipment, which will support these THC processing licenses, as well as efforts underway to develop multiple other Nano products to serve additional major potential markets, such as sleep, immune booster and hair restoration. Many of these additional markets are multiples in size of the THC opportunity, which is already a major market opportunity.”

To view the full press release, visit https://ibn.fm/kg4CJ

About Pressure BioSciences Inc.

Pressure BioSciences is a global leader in providing innovative, broadly enabling, high-pressure-based solutions for a range of industries, including biotechnology, pharmaceutical, nutraceutical, and agrochemical, as well as food and beverage manufacturing. The company’s products utilize both constant and alternating pressure. Pressure BioSciences’ patented enabling technology platform, Pressure Cycling Technology (“PCT”), utilizes alternating cycles of pressure to control bio-molecular interactions (such as cell lysis and biomolecule extraction) safely and reproducibly. PCT-based products are beginning to be widely used for biomarker and target discovery, drug design and development, biotherapeutics characterization and quality control, soil and plant biology, forensics, and counter-bioterrorism applications. The company has recently expanded its market opportunities with the acquisition of the BaroFold(TM) patented technology platform, allowing it to enter the bio-pharma contract services and GMP manufacturing equipment sector. Pressure BioSciences has also developed the scalable and high-efficiency pressure-based UltraShear Technology(TM) (UltraShear(TM) or UST(TM)) platform, which allows for the creation of stable nanoemulsions of otherwise immiscible fluids. It also allows for the preparation of higher quality, homogenized, extended shelf-life or room temperature-stable low-acid liquid foods that cannot be effectively preserved using existing non-thermal technologies. The company’s commitment to innovation and cutting-edge technology has established PBIO as a leader in the high-pressure industry, providing unique and effective solutions to its customers. For more information about the company, visit www.PressureBioSciences.com.

NOTE TO INVESTORS: The latest news and updates relating to PBIO are available in the company’s newsroom at http://ibn.fm/PBIO

About InvestorWire

InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent.

As part of its service, InvestorWire provides coverage of noteworthy announcements. To further expand visibility of achievements being made throughout a multitude of sectors, InvestorWire’s syndication partners have extended the digital coverage to include individual broadcasts on financial websites and platforms visited by millions of investors daily.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer

InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.InvestorWire.com
Editor@InvestorWire.com

InvestorWire is part of the InvestorBrandNetwork